Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Placebo
DRUG: Veliparib
DRUG: Carboplatin
DRUG: Temozolomide
DRUG: Paclitaxel

Sponsor

AbbVie